113
Participants
Start Date
July 31, 2015
Primary Completion Date
December 31, 2019
Study Completion Date
December 31, 2019
Anlotinib
Anlotinib p.o. qd
Placebo
Placebo p.o. qd
Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing
20th Floor, Block C, Lake Road, Hexi District, Tianjin Medical University Cancer Institute and Hospital ., Tianjin
Zhejiang Cancer Hospital, Hangzhou
West China Hospital Of Sichuan University, Chongqing
Chongqing Cancer Hospital, Chongqing
Union Hospital Tongji Medical College Huazhong University of Science and Technology, Wuhan
Beijing Tongren Hospital, Beijing
Peking Union Medical College Hospital, Beijing
Fujian Cancer Hospital, Fuzhou
Gansu Province Tumor Hospital, Lanzhou
Sun Yat-Sen University Cancer Center, Guozhou
Harbin medical university affiliated tumor hospital, Harbin
Henan Province Tumor Hospital, Luoyan
Hunan Province Tumor Hospital, Changsha
Jiangsu province tumor hospital, Nanjing
Jilin Cancer Hospital, Changchun
Liaoning Province Tumor Hospital, Shenyang
Cancer Hospital of Fudan University, Shanghai
The First Affiliated Hospital of Kunming Medical University, Kunming
Lead Sponsor
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
INDUSTRY